ArticleJACC. Case reports2025
Challenges in Diagnosing Systemic Amyloidosis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Automated identification of cardiac amyloidosis using cross-modal neural networks on [Formula: see text]-Pyrophosphate SPECT imaging and clinical data.The international journal of cardiovascular imaging · 2026Article
- Hereditary Transthyretin Cardiac Amyloidosis With Severe Left Ventricular Outflow Tract Obstruction Mimicking Hypertrophic Obstructive Cardiomyopathy.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of cardiac amyloidosis can be achieved noninvasively for transthyretin amyloid cardiomyopathy through nuclear scintigraphy with bone tracers. For other subtypes of cardiac amyloidosis (eg, light-chain amyloid cardiomyopathy), or in cases of suspected transthyretin amyloid cardiomyopathy with nondiagnostic scintigraphy results, histologic confirmation via tissue biopsy and amyloid subtype identification is required. CASE SUMMARY: We present a case of a 66-year-old male with heart failure and left ventricular hypertrophy with evidence of systemic amyloidosis. Despite multiple biopsies of different organs and extensive testing, including mass spectrometry, the amyloid subtype could not be clearly identified. The patient's condition rapidly deteriorated without the initiation of targeted therapy, leading to multiple hospitalizations and an unfavorable prognosis. TAKE-HOME MESSAGE: This case emphasizes the diagnostic challenges in cardiac amyloidosis and highlights the importance of continuous advancements in diagnostic techniques to improve patient outcomes with this complex disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.